Drugs / FKC288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05978661 | Aug 2023 → Jun 2025 | AL amyloidosis | Nanjing University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FKC288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05978661 ↗ |
| Action | Deplete | “complete elimination of pathogenic plasma and B cells” PMID 41920709 ↗ Apr 2026 |
| Modality | Cell therapy | “FKC288 chimeric antigen receptor (CAR) modified T cells” NCT05978661 ↗ |
| Target | CD19 | “BCMA-CD19 dual-targeted CAR- T -cell therapy” PMID 41920709 ↗ Apr 2026 |